ALK and non-small cell lung carcinoma: Patients with EGFR and ALK mutations have been excluded from the clinical trials of combination therapy of immune checkpoint inhibitor (ICI) with cytotoxic chemotherapy due to their low efficacy, and the development of treatment has been mainly focused on patients with NSCLC without driver mutations.